|
Market Research Report
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
| Published by |
BioSeeker Group AB |
| Published |
March, 2009 |
Product code |
83663 |
| Content info |
2300 pages |
| Price |
|
|
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy published by BioSeeker Group AB in March, 2009. This report consists of 2300 pages and the price starts from US $ 11528.
Abstract
With the emergence of new technologies and an increased understanding of the
biological basis for cancer evolution, the molecular changes that distinguish
malignant-cells from normal cells are becoming increasingly apparent, offering
a growing range of potential drug targets in the form of altered genes,
proteins or corrupted pathways. Drug targets are the critical link between
drugs and their role in the treatment of medical disorders.
This report, Complete Target Atlas in Oncology Drug Development, is written
for you to identify your competition and understand which targeting strategies
are at work within the cancer drug development landscape. It allows you to
pin-point which competitors drugs' clinical out-come may have bearing on your
own drug development and who are developing sequels to successful drugs. This
report also helps you to locate white-spots in the competitive landscape,
giving you little or no competition. Conversely it may reveal unexpected
competition for you.
Complete Target Atlas in Oncology Drug Development is a multi-report made up
by nine different and independent target reports covering five different
targeted therapies areas and four major tumor types in detail:
- Targeted Therapy Strategies in Cancer
- Apoptosis
- Angiogenesis/VDA/VTA
- Antibodies
- Immunomodulators & Vaccines
- Protein Kinase Inhibitors
- Major Tumor Types
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
Each report subject (click on each subject for detailed information) covers:
- Compound strategies based on sub-cellular localization of cancer drug
targets
- The Cancer Genome Project and cancer drug targets
- Expression levels of identified drug targets in selected tumor type
- Pathway analysis of cancer drug targets
- Target-target interactions among identified cancer targets
- Structure-based drug design in 9 s stimulated by available structure data
on biological targets
- Unique, in-depth, drug target validating profiles, highlighting twelve
themes about the drug target, i.e. protein-protein interaction with other
cancer drug targets, pursued cancer indications, drugs under development,
presence in the Cancer Genome Project etc.
- Drug-target interactome
- The progression and maturity of cancer targets: New and unique cancer drug
targets
- Indication specific reports deal with targets by R&D approach in specified
cancer types, whereas targeted therapy specific reports deal with targets by
cancer indication.
- Cancer drug target profiles by investigator
This report is an open landscape of resources to build, fuel, and drive your
scientific competitive vehicle for the advancement of cancer drugs. It will
assist you in lead commercial analysis and product strategy thinking to build
and nurture current and future portfolio of drug candidates and R&D alliances.
This report will help you to streamline your analysis of new as well as of
established drug targets, when looking for clinical proofs, indication
selection, competitive environment etc.
|
